Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

Lancet. 1984 May 12;1(8385):1046-7. doi: 10.1016/s0140-6736(84)91452-1.


A young woman, bedbound with severe pulmonary hypertension, responded to intravenous epoprostenol with a fall in pulmonary vascular resistance, improved oxygenation, and a rise in exercise tolerance. For thirteen months, continuous infusion of epoprostenol has enabled her to live independently at home.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Pressure / drug effects
  • Cardiac Output / drug effects
  • Epoprostenol / administration & dosage*
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Infusions, Parenteral
  • Pulmonary Circulation / drug effects
  • Time Factors
  • Vascular Resistance / drug effects


  • Epoprostenol